ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies (NASDAQ: IPA) is a contract research organization focused on the discovery, development and optimization of antibodies. The company offers a full suite of services that span early‐stage discovery through to candidate selection, providing clients with monoclonal and polyclonal antibody solutions, custom immunochemistry assay development, and cell line engineering support. Leveraging multiple discovery platforms, ImmunoPrecise Antibodies tailors its approach to meet the unique requirements of therapeutic, diagnostic and research applications.

The company’s service offerings include hybridoma generation, phage display, single B cell screening and recombinant antibody engineering. These technologies enable rapid identification and humanization of high‐affinity antibody candidates. In addition, ImmunoPrecise Antibodies provides cell line development and protein expression support, helping clients to advance their molecules through scalable biomanufacturing processes and analytical characterization.

Headquartered in Victoria, British Columbia, ImmunoPrecise Antibodies maintains laboratories in North America, Europe and Asia Pacific to serve a global client base that ranges from emerging biotech firms to large pharmaceutical companies. Since its inception, the company has expanded its footprint through targeted facility investments, supporting projects across immuno‐oncology, autoimmunity, neuroscience and infectious disease research.

Under the leadership of President and CEO Dr. Paul R. Lem, PhD, ImmunoPrecise Antibodies has pursued strategic growth through both organic development and selective asset acquisitions. The management team combines expertise in antibody science, drug development and business operations, positioning the company to address evolving client needs in the rapidly advancing field of biotherapeutics.

Key Stats

• Today's Range: $2.00 to $2.24
• 50-Day Range: $1.81 to $3.20
• 52-Week Range: $0.43 to $3.25
• Volume: 1.97 million shs
• Average Volume: 2.11 million shs
• Market Capitalization: $96.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPA Stock Analysis - Frequently Asked Questions

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) announced its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.02. The company had revenue of $5.06 million for the quarter, compared to analyst estimates of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative trailing twelve-month return on equity of 40.62%.
Read the conference call transcript.

What other stocks do shareholders of ImmunoPrecise Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 5/06/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPA
• CIK: 1715925
• Web: www.immunoprecise.com
• Phone: 250-483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.69 million
• Net Margins: -122.10%
• Pretax Margin: -139.75%
• Return on Equity: -40.62%
• Return on Assets: -22.19%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 2.08
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $17.59 million
• Price / Sales: 5.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 5.66

Miscellaneous

• Outstanding Shares: 46,150,000
• Free Float: 43,002,000
• Market Cap: $96.68 million
• Optionable: Not Optionable
• Beta: 0.53